Alpha-Melanocyte-Stimulating Hormone (α-MSH) is a 13-amino acid endogenous neuropeptide that is a primary cleavage product of the proopiomelanocortin (POMC) precursor protein. It was first identified for its role in stimulating melanin production in melanocytes, leading to skin pigmentation. Beyond this classic function, α-MSH is now recognized as a critical pleiotropic peptide with significant roles in the central nervous system and peripheral tissues, acting as a potent anti-inflammatory and immunomodulatory agent. Its discovery and subsequent research have revealed a broad network of biological activities mediated through melanocortin receptors, positioning it as a key regulator in processes ranging from feeding behavior and energy homeostasis to inflammation control and cytoprotection.
The significance of α-MSH extends into numerous research fields due to its ability to modulate immune responses and promote homeostasis. It is considered a fundamental component of the body’s endogenous anti-inflammatory system, often released in response to inflammatory stimuli. Research into synthetic and stabilized analogs, such as NDP-α-MSH (Melanotan I) and afamelanotide (Scenesse), has further highlighted its therapeutic potential, particularly in dermatological conditions and disorders involving dysregulated inflammation. Its broad receptor affinity and central role in the melanocortin system make it a pivotal molecule for understanding neuroendocrine-immune communication.
Quick Facts
| Also Known As | α-MSH, alpha-MSH, alpha-Melanotropin, alpha-Melanocortin, Ac-alpha-MSH, NDP-alpha-MSH |
|---|---|
| Sequence | Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 |
| Molecular Formula | C77H109N21O19S |
| Molecular Weight | 1664.91 Da |
Research Parameters
| Half-Life | ~30-50 minutes (endogenous, in plasma) |
|---|---|
| Stability | Lyophilized powder is stable for at least 24 months when stored at -20°C, protected from light and moisture. After reconstitution in sterile solvent, solutions are typically stable for up to 7-14 days when stored at 2-8°C, although immediate use is recommended for optimal activity. |
| Solubility | Bacteriostatic Water (0.9% Benzyl Alcohol), Sterile Water, or Phosphate-Buffered Saline (PBS). Acetic acid (0.1%) may be used for enhanced solubility of larger quantities. |
| Vial Size | 2 mg |
| Storage (Lyophilized) | -20°C, protect from light and moisture |
| Storage (Reconstituted) | 2-8°C (refrigerated), protected from light, for short-term storage (typically ≤14 days) |
| Typical Research Dose | Research doses vary; common in vitro/vivo research ranges are 1-100 nM in vitro, and 10-300 mcg/kg in vivo (animal models). |
| Cycle Parameters | Research protocols are highly variable. In chronic animal studies, daily subcutaneous injection for 1-8 weeks is common. In human clinical studies with analogs, cycles may involve single subcutaneous implants lasting several months or daily/subcutaneous administration for defined periods (e.g., 10-14 days). |
| Amino Acid Count | 15 |
Mechanism of Action
The primary mechanism of action of α-MSH involves binding to and activating melanocortin receptors (MCRs), a family of five G-protein-coupled receptors (MC1R through MC5R) with distinct tissue distributions. Activation of these receptors triggers intracellular signaling cascades, predominantly involving the stimulation of adenylate cyclase, increased cyclic AMP (cAMP) production, and subsequent activation of protein kinase A (PKA). This foundational pathway mediates the diverse physiological effects of the peptide, from pigment production to immune modulation.
MC1R Pathway: This is the high-affinity receptor for α-MSH, predominantly expressed on melanocytes and immune cells (e.g., macrophages, neutrophils). Activation on melanocytes stimulates melanogenesis via upregulation of tyrosinase and other melanogenic enzymes. On immune cells, MC1R activation exerts potent anti-inflammatory effects by inhibiting the production and release of pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6) and chemokines, while promoting the release of anti-inflammatory mediators like IL-10.
Central Nervous System Pathways: α-MSH acts as an agonist at MC3R and MC4R in the brain, particularly within the hypothalamus. Activation of MC4R is a primary mediator of its anorexigenic (appetite-suppressing) effects, influencing energy homeostasis and feeding behavior. These central actions also contribute to its modulatory effects on autonomic functions and sexual behavior.
Peripheral Anti-inflammatory and Cytoprotective Pathways: Beyond MC1R on leukocytes, α-MSH can modulate inflammation by inhibiting NF-κB nuclear translocation and activation, a master regulator of inflammatory gene expression. It also promotes cytoprotective responses, such as reducing oxidative stress and inhibiting apoptotic pathways in various cell types, contributing to tissue protection in models of injury.
Research Applications
Dermatological Research: α-MSH and its analogs are extensively studied for conditions related to pigmentation and photoprotection. Research indicates potential for treating erythropoietic protoporphyria (where afamelanotide is approved), vitiligo, and actinic keratosis. Its role in stimulating eumelanin production is investigated for providing endogenous protection against UV radiation damage.
Immunology and Inflammation Research: As a key endogenous anti-inflammatory peptide, α-MSH is a major focus in models of autoimmune and inflammatory diseases. Studies explore its efficacy in experimental models of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and sepsis. Its ability to downregulate both innate and adaptive immune responses positions it as a template for novel immunomodulatory therapies.
Neuroprotection and CNS Disorders: Research investigates the neuroprotective and anti-inflammatory effects of α-MSH in the central nervous system. Potential applications are being explored in models of stroke, traumatic brain injury, Parkinson's disease, and Alzheimer's disease, where its inhibition of neuroinflammation and modulation of glial cell activity may confer therapeutic benefit.
Metabolic and Obesity Research: Due to its central role in regulating appetite and energy expenditure via hypothalamic MC3R and MC4R, α-MSH is a significant molecule in obesity and metabolic syndrome research. Studies aim to understand and potentially harness its anorexigenic pathways to develop treatments for obesity and related metabolic disorders.
Safety & Side Effects
In animal studies, α-MSH is generally well-tolerated, reflecting its endogenous nature. Primary observed effects relate to its pharmacological actions: hyperpigmentation (darkening of skin and fur) is common and expected. At high doses, transient effects on grooming behavior and stretching (a sign of MC receptor activation) have been noted in rodents. In human clinical trials with stabilized analogs, anecdotally reported side effects include nausea, flushing, yawning, and spontaneous penile erections (due to central MC receptor activation). Theoretical concerns based on its mechanism include potential impacts on appetite and energy balance with chronic administration. No significant organ toxicity has been consistently reported in controlled research settings at physiological or moderately supraphysiological doses.
Dosage Information
This information is derived from published preclinical and clinical research studies only and does not constitute medical advice. For research purposes, administration parameters vary widely by model and analog. For the endogenous peptide and shorter analogs in research: Typical subcutaneous or intravenous injection is used. Dosing in rodent models often ranges from 10 to 300 mcg/kg per administration. In early human clinical studies with analogs like afamelanotide, subcutaneous implants providing sustained release (e.g., 16 mg over months) have been used. Frequency can be single-dose, daily, or intermittent based on the study protocol. Duration in research cycles spans from acute single administrations to chronic studies over several weeks.
References
Catania, A., Airaghi, L., Garofalo, L., Cutuli, M., & Lipton, J. M. The neuropeptide alpha-MSH in host defense. Annals of the New York Academy of Sciences, 1998.
Luger, T. A., Brzoska, T., Scholzen, T. E., Kalden, D. H., & Brzoska, T. The role of alpha-MSH as a modulator of cutaneous inflammation. Annals of the New York Academy of Sciences, 2000.
Getting, S. J., Christian, H. C., Flower, R. J., & Perretti, M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis & Rheumatism, 2002.
Mountjoy, K. G., Robbins, L. S., Mortrud, M. T., & Cone, R. D. The cloning of a family of genes that encode the melanocortin receptors. Science, 1992.
Langendonk, J. G., Balwani, M., Anderson, K. E., et al. Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine, 2015.
Wikberg, J. E., Muceniece, R., Mandrika, I., et al. New aspects on the melanocortins and their receptors. Pharmacological Research, 2000.
Brzoska, T., Luger, T. A., Maaser, C., Abels, C., & Böhm, M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews, 2008.